Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study

This study has been withdrawn prior to enrollment.
(The study have been stoped because the protocol is going to be modify.)
Sponsor:
Information provided by:
University of Manitoba
ClinicalTrials.gov Identifier:
NCT00493428
First received: June 27, 2007
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

Recent studies indicate that liver cancer cells possess a receptor called the GABA-B receptor that when activated, inhibits the spread of cancer cells in test tubes. One of the drugs that activate these receptors is Baclofen, an agent that was originally developed to treat patients with various neurologic disorders. In this study, patients with recently identified liver cancer will be treated with Baclofen in an attempt to prevent or delay spread of the cancer beyond the liver. The time it takes for liver cancer to spread in the patients will be compared to the results obtained from patients enrolled in previous studies where Baclofen was not used.


Condition Intervention Phase
Hepatocellular Carcinoma
Drug: Baclofen
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study

Resource links provided by NLM:


Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization. [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Document and compare the effects of the GABAb receptor agonist Baclofen on changes in serum tumor markers ( alpha-fetoprotein andd CA19-9 levels) in patients with no-metastatic HCC at diagnosis. [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: July 2007
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Baclofen
    Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
    Other Name: Lioresal,Nu-Baclo
Detailed Description:

A total of 47 consecutive patients with radiologic or histologic evidence of non metastatic liver cancer will be enrolled over a 2-4 year period. Subjects will receive oral Baclofen at the manufacturer's suggested maximal dose. Clinical, hematologic, biochemical, and radiologic features of liver function, tumor metastasis and recurrence will be monitored at regular time intervals over a 2 year treatment period. The primary study end point will be the event of interest (time to metastasis or recurrence). Secondary end points will include time to metastasis following recurrence, objective tumor responses (complete, partial and non response), response duration, survival and safety. It is hoped the results of this study will permit liver cancer patients to remain candidates for surgical resection and transplantation longer than would otherwise have been the case.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A diagnosis of HCC and no evidence of extra-hepatic metastases on CT/MRI scan of the abdomen, CT of the chest and brain and a negative bone scan.
  • Patients undergoing local therapy (resection, ablation or chemoembolization) and those listed for liver transplantation will not be excluded from participating in the study.
  • Patients with multiple space occupying lesions within the liver (but no evidence of extra-hepatic metastases) will continue to be eligible (the distinction between regenerative nodules and multi-focal HCC versus intra-hepatic metastases can not be made with certainty by presently available techniques).
  • Karnofsky Performance Status (KPS) ≥ 60 %.
  • Age 18 years or greater.
  • Life expectancy of at least 12 weeks.
  • Concomitant Medications
  • Patients should be on stable doses of other medications (no change in dose for two weeks prior to study initiation) when entered into the study.
  • Patient consent must be obtained from all patients prior to entry into the trial.
  • Patients must be accessible for treatment and follow-up i.e. residing within reasonable geographical limits of the study site.

Exclusion Criteria:

  • Any investigational agent within a minimum of 6 weeks prior to study treatment.
  • Pregnant or lactating women; women or men of childbearing potential unless using effective contraception. Patients capable of reproduction must agree to use appropriate methods of contraception during the study and for six months afterwards. Female patients of childbearing potential must have a negative urine pregnancy test within 14 days of study enrollment.
  • Patients whose partners are pregnant.
  • Other serious illness or medical conditions which would not permit the patient to be managed according to the protocol including:

    • History of a psychiatric disorder which would impair the ability to obtain consent or follow-up tumor imaging.
    • Active uncontrolled infection.
  • Any known defect in GABA metabolism or hypersensitivity to Baclofen.
  • Patients with previous organ allograft or taking immunomodulatory drugs.
  • Renal failure not being managed by dialysis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00493428

Locations
Canada, Manitoba
Liver Unit, health sciences Centre
Winnipeg, Manitoba, Canada
Liver Unit, Section of Hepatology, Department of Medicine,Health Sciences Centre
Winnipeg, Manitoba, Canada, R3E 3P4
Sponsors and Collaborators
University of Manitoba
Investigators
Principal Investigator: Minuk Y Minuk, MD, FRCPC University of Manitoba
  More Information

No publications provided

Responsible Party: Minuk Gerald, Liver Unit, Health Sciences Centre
ClinicalTrials.gov Identifier: NCT00493428     History of Changes
Other Study ID Numbers: B2006:156
Study First Received: June 27, 2007
Last Updated: May 15, 2014
Health Authority: Canada: Health Canada

Keywords provided by University of Manitoba:
Hepatocellular Carcinoma
GABAergic Activity
Baclofen

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 20, 2014